Triplet Chemotherapy Does Not Improve Disease-Free Survival in High-Risk Stage III Colon Cancer

https://www.medscape.com/viewarticle/triplet-chemotherapy-does-not-improve-disease-free-survival-2026a100152b?src= Adjuvant modified leucovorin, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) did not improve disease-free survival (DFS) compared with modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) in patients with completely resected, high-risk stage III colon cancer, a randomised phase 3 trial found.